Inflammatory cell death in cancer: linking pyroptosis, necroptosis, ferroptosis, PANoptosis, and antitumor immunity
4 affiliations
- 1Department of Anesthesiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan
- 2Department of Clinical Pharmacy, Chongqing Medical University
- 3Department of Medical Affairs, Shandong Academy of Occupational Health and Occupational Medicine, Occupational Disease Hospital of Shandong First Medical University, Shandong Province Hospital of Occupational Diseases
- 4Department of Oncology, Fengjie County People’s Hospital
Abstract
Inflammatory cell death has emerged as a critical interface between cancer therapy and antitumor immunity. Unlike relatively non-inflammatory cell death, pyroptosis, necroptosis, ferroptosis, and PANoptosis can generate or release damage-associated molecular patterns (DAMPs), tumor antigens, inflammatory cytokines, oxidized lipids, and nucleic acid ligands that reshape the tumor microenvironment. These death programs link therapeutic stress to dendritic cell activation, antigen cross-presentation, type I interferon signaling, cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) signaling, and cytotoxic T-cell responses. However, their immune consequences are highly context dependent. Preclinical studies suggest that selected inflammatory cell death pathways may improve responses to immune checkpoint blockade under defined experimental conditions; however, these effects vary with tumor type, cellular context, and treatment modality, and their clinical relevance remains to be established. Conversely, ferroptosis or PANoptosis in suppressive myeloid cells can reinforce immune evasion. This review summarizes recent experimental advances connecting inflammatory cell death with tumor immunity, focusing on molecular executors, immune mediators, therapeutic opportunities, biomarkers, and translational challenges. We propose that future cancer therapy should move beyond simply inducing tumor cell death toward designing immune-productive death programs that are spatially controlled, cell-type selective, and rationally synchronized with immunotherapy.
Related
- Inflammasome-mediated cell death pathways in female reproductive disorders: from apoptosis, pyroptosis, and necroptosis to PANoptosis.
- NecroFerrins as dual therapeutic inhibitors targeting necroptosis and ferroptosis
- Keratinocyte necroptosis in inflammatory skin diseases and acute epidermal injury: mechanisms, evidence, and therapeutic implications
- Ferroptosis-pyroptosis crosstalk in neonatal necrotizing enterocolitis: epithelial barrier failure, immune amplification, and precision targeting.
- Mitochondrial quality control at the ferroptosis-pyroptosis interface in diabetic cardiomyopathy: a narrative critical synthesis
BibTeX
@article{li2026inflammatory,
title = {{Inflammatory cell death in cancer: linking pyroptosis, necroptosis, ferroptosis, PANoptosis, and antitumor immunity}},
author = {Shanshan Li and Zihan Zhou and Peng Li and Tao Zheng},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.2004224},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2004224/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Inflammatory cell death in cancer: linking pyroptosis, necroptosis, ferroptosis, PANoptosis, and antitumor immunity
AU - Shanshan Li
AU - Zihan Zhou
AU - Peng Li
AU - Tao Zheng
PY - 2026
DA - 2026/10/26
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2004224
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2004224/full
AB - Inflammatory cell death has emerged as a critical interface between cancer therapy and antitumor immunity. Unlike relatively non-inflammatory cell death, pyroptosis, necroptosis, ferroptosis, and PANoptosis can generate or release damage-associated molecular patterns (DAMPs), tumor antigens, inflammatory cytokines, oxidized lipids, and nucleic acid ligands that reshape the tumor microenvironment. These death programs link therapeutic stress to dendritic cell activation, antigen cross-presentation, type I interferon signaling, cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) signaling, and cytotoxic T-cell responses. However, their immune consequences are highly context dependent. Preclinical studies suggest that selected inflammatory cell death pathways may improve responses to immune checkpoint blockade under defined experimental conditions; however, these effects vary with tumor type, cellular context, and treatment modality, and their clinical relevance remains to be established. Conversely, ferroptosis or PANoptosis in suppressive myeloid cells can reinforce immune evasion. This review summarizes recent experimental advances connecting inflammatory cell death with tumor immunity, focusing on molecular executors, immune mediators, therapeutic opportunities, biomarkers, and translational challenges. We propose that future cancer therapy should move beyond simply inducing tumor cell death toward designing immune-productive death programs that are spatially controlled, cell-type selective, and rationally synchronized with immunotherapy.
SN - 1664-3224
ER -